PATIENTS
A SIMPLE WAY TO DETECT
STOMACH CANCER, EARLY.
CORE CONCEPT
GastroMDx is a non-invasive, blood-based diagnostic test developed by Ilico Genetics to detect gastric (stomach) cancer in its earliest stages — often years before traditional methods can identify signs of disease. It represents a breakthrough in early detection technology by allowing clinicians to identify molecular changes long before symptoms appear.
KEY DIFFERENTIATORS
-
Simple blood draw, eliminating the need for endoscopy in early screening phases.
-
Detects early-stage disease (when survival rates are highest) by identifying unique biomarker profiles.
-
Designed to find cancer before physical symptoms appear.
-
Lower cost and minimal discomfort make it feasible for widespread use across at-risk populations.
EARLY DETECTION STARTS WITH YOU.
We’re conducting a clinical study to evaluate GastroMDx™. By taking part, you’ll help advance research that could change how doctors find and treat this disease for generations to come. If you’re interested in joining our study, answer a few short questions to see if you qualify. A member of our research team will reach out with more details and next steps.